RU2223782C2 - Средство для лечения патологического костного метаболизма - Google Patents
Средство для лечения патологического костного метаболизма Download PDFInfo
- Publication number
- RU2223782C2 RU2223782C2 RU2001114216/15A RU2001114216A RU2223782C2 RU 2223782 C2 RU2223782 C2 RU 2223782C2 RU 2001114216/15 A RU2001114216/15 A RU 2001114216/15A RU 2001114216 A RU2001114216 A RU 2001114216A RU 2223782 C2 RU2223782 C2 RU 2223782C2
- Authority
- RU
- Russia
- Prior art keywords
- agent
- polysaccharide
- ocif
- derivatives
- osseous
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области медицины и касается средства для лечения патологического костного метаболизма. Изобретение заключается в том, что средство включает по меньшей мере одно вещество, выбранное из группы, состоящей из фактора, ингибирующего остеокластогенез (OCIF), его гомологов и его вариантов, и полисахарид или его производные. В качестве полисахарида или его производных могут использоваться гепарин, декстрансульфат и им подобные. Изобретение обеспечивает отличный терапевтический эффект на такие виды патологического костного метаболизма, как остеопороз, гиперкальцемия или хронический суставной ревматизм, и имеет устойчивую активность. 2 с. и 4 з.п. ф-лы, 10 ил.
Description
Текст описания в факсимильном виде (см. графическую часть)е
Claims (6)
1. Средство для лечения патологического костного метаболизма, включающее, по меньшей мере, одно вещество, выбранное из группы, состоящей из фактора, ингибирующего остеокластогенез (OCIF), его гомологов и его вариантов, и полисахарида или его производных, в котором количество полисахарида или его производных в 1 - 100 раз превышает количество OCIF, его гомологов или его вариантов.
2. Средство для лечения патологического костного метаболизма по п.1, в котором количество полисахарида или его производных в 1 - 16 раз превышает количество OCIF, его гомологов или его вариантов.
3. Средство для лечения патологического костного метаболизма по п.1, в котором OCIF представляет собой человеческий OCIF.
4. Средство для лечения патологического костного метаболизма по п.1, в котором полисахарид представляет собой гепарин, пектин и/или карагенан.
5. Средство для лечения патологического костного метаболизма по п.1, в котором производное полисахарида представляет собой декстрансульфат.
6. Способ усиления активности фактора, ингибирующего остеокластогенез, включающий добавление к фактору, ингибирующему остеокластогенез (OCIF), его гомологу или варианту по п.1 полисахарида или его производных.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32287498 | 1998-10-28 | ||
| JP10-322874 | 1998-10-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2001114216A RU2001114216A (ru) | 2003-03-10 |
| RU2223782C2 true RU2223782C2 (ru) | 2004-02-20 |
Family
ID=18148585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001114216/15A RU2223782C2 (ru) | 1998-10-28 | 1999-10-28 | Средство для лечения патологического костного метаболизма |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6919312B2 (ru) |
| EP (1) | EP1127578A4 (ru) |
| JP (1) | JP3860415B2 (ru) |
| KR (1) | KR20010082272A (ru) |
| CN (1) | CN1183961C (ru) |
| AU (1) | AU755422B2 (ru) |
| BR (1) | BR9914834A (ru) |
| CA (1) | CA2347107A1 (ru) |
| CZ (1) | CZ20011378A3 (ru) |
| HK (1) | HK1042847A1 (ru) |
| HU (1) | HUP0104126A3 (ru) |
| IL (1) | IL142557A0 (ru) |
| MX (1) | MXPA01004225A (ru) |
| NO (1) | NO20012106L (ru) |
| NZ (1) | NZ511506A (ru) |
| PL (1) | PL347559A1 (ru) |
| RU (1) | RU2223782C2 (ru) |
| TR (1) | TR200101146T2 (ru) |
| TW (1) | TW529954B (ru) |
| WO (1) | WO2000024416A1 (ru) |
| ZA (1) | ZA200103296B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| IL158152A0 (en) * | 2001-04-03 | 2004-03-28 | Nestle Sa | Osteoprotegerin in milk |
| CZ20022231A3 (cs) * | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) * | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
| AU2003242265A1 (en) * | 2002-06-07 | 2003-12-22 | Sankyo Company, Limited | Combined effects of therapeutic or preventive agent composition for bone breakage |
| CN101184780B (zh) | 2005-05-05 | 2012-10-03 | 森馨香料公司 | β-葡聚糖和甘露聚糖的制备 |
| TW200820980A (en) * | 2006-10-02 | 2008-05-16 | Nat Inst For Materials Science | A sustained-release preparation having osteoconductive activity |
| WO2008077257A1 (en) * | 2006-12-22 | 2008-07-03 | Mathys Ag Bettlach | Precursor for the preparation of a pasty bone replacement material by admixture of a liquid |
| SG181615A1 (en) * | 2009-12-09 | 2012-07-30 | Agency Science Tech & Res | Glycosaminoglycan mixtures |
| CN113088487B (zh) * | 2020-04-30 | 2022-12-06 | 威海见生生物技术有限公司 | 一种间充质干细胞成脂转化抑制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2604135B2 (ja) * | 1986-02-28 | 1997-04-30 | ライオン株式会社 | 口腔骨疾患治療剤 |
| IL91438A (en) * | 1989-08-25 | 1995-03-30 | Bukh Meditec | Preparation for treating dental disease |
| TW318142B (ru) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US20030207827A1 (en) | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| EP0911342B2 (en) | 1997-04-15 | 2013-05-22 | Daiichi Sankyo Company, Limited | Novel protein and process for producing the same |
| US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| KR100547395B1 (ko) | 1997-09-24 | 2006-02-01 | 산쿄 가부시키가이샤 | 골대사이상증의 진단방법 |
| DE69904818T2 (de) | 1998-06-15 | 2003-10-09 | Takeda Chemical Industries, Ltd. | Thienodipyridinderivate, ihre herstellung und verwendung |
| TR200101146T2 (tr) | 1998-10-28 | 2001-09-21 | Sankyo Co., Ltd. | Kemik-patobolizmasını tedavi edici madde. |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| AU6788900A (en) * | 1999-09-03 | 2001-04-10 | Amgen, Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| CA2394536A1 (en) | 1999-12-16 | 2001-06-21 | Amgen Inc. | Tnfr/opg-like molecules and uses thereof |
| CZ20022231A3 (cs) | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu |
| EP1482978A1 (en) | 2002-03-01 | 2004-12-08 | Sankyo Company, Limited | Pharmaceutical composition comprising osteoclastogenesis inhibitory factor |
-
1999
- 1999-10-28 TR TR2001/01146T patent/TR200101146T2/xx unknown
- 1999-10-28 CZ CZ20011378A patent/CZ20011378A3/cs unknown
- 1999-10-28 AU AU64877/99A patent/AU755422B2/en not_active Ceased
- 1999-10-28 JP JP2000578024A patent/JP3860415B2/ja not_active Expired - Fee Related
- 1999-10-28 EP EP99952793A patent/EP1127578A4/en not_active Withdrawn
- 1999-10-28 WO PCT/JP1999/005963 patent/WO2000024416A1/ja not_active Application Discontinuation
- 1999-10-28 TW TW088118658A patent/TW529954B/zh not_active IP Right Cessation
- 1999-10-28 IL IL14255799A patent/IL142557A0/xx unknown
- 1999-10-28 RU RU2001114216/15A patent/RU2223782C2/ru not_active IP Right Cessation
- 1999-10-28 HU HU0104126A patent/HUP0104126A3/hu unknown
- 1999-10-28 MX MXPA01004225A patent/MXPA01004225A/es unknown
- 1999-10-28 KR KR1020017005365A patent/KR20010082272A/ko not_active Application Discontinuation
- 1999-10-28 CA CA002347107A patent/CA2347107A1/en not_active Abandoned
- 1999-10-28 PL PL99347559A patent/PL347559A1/xx not_active Application Discontinuation
- 1999-10-28 BR BR9914834-0A patent/BR9914834A/pt not_active IP Right Cessation
- 1999-10-28 NZ NZ511506A patent/NZ511506A/xx unknown
- 1999-10-28 CN CNB998128287A patent/CN1183961C/zh not_active Expired - Fee Related
-
2001
- 2001-04-12 US US09/834,008 patent/US6919312B2/en not_active Expired - Fee Related
- 2001-04-23 ZA ZA200103296A patent/ZA200103296B/en unknown
- 2001-04-27 NO NO20012106A patent/NO20012106L/no unknown
-
2002
- 2002-06-05 HK HK02104289.0A patent/HK1042847A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1042847A1 (zh) | 2002-08-30 |
| PL347559A1 (en) | 2002-04-08 |
| JP3860415B2 (ja) | 2006-12-20 |
| WO2000024416A1 (fr) | 2000-05-04 |
| HUP0104126A3 (en) | 2004-07-28 |
| TW529954B (en) | 2003-05-01 |
| ZA200103296B (en) | 2001-10-25 |
| US20010031725A1 (en) | 2001-10-18 |
| AU755422B2 (en) | 2002-12-12 |
| IL142557A0 (en) | 2002-03-10 |
| US6919312B2 (en) | 2005-07-19 |
| MXPA01004225A (es) | 2002-06-04 |
| NO20012106L (no) | 2001-06-21 |
| EP1127578A4 (en) | 2004-12-15 |
| AU6487799A (en) | 2000-05-15 |
| CN1325310A (zh) | 2001-12-05 |
| CZ20011378A3 (cs) | 2001-10-17 |
| NO20012106D0 (no) | 2001-04-27 |
| TR200101146T2 (tr) | 2001-09-21 |
| EP1127578A1 (en) | 2001-08-29 |
| KR20010082272A (ko) | 2001-08-29 |
| BR9914834A (pt) | 2001-08-14 |
| NZ511506A (en) | 2004-02-27 |
| HUP0104126A2 (hu) | 2002-03-28 |
| CA2347107A1 (en) | 2000-05-04 |
| CN1183961C (zh) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2223782C2 (ru) | Средство для лечения патологического костного метаболизма | |
| BR0212809A (pt) | Inibidores de anticorpos de gdf-8 e usos dos mesmos | |
| ATE443523T1 (de) | Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust | |
| BR9714155A (pt) | Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina. | |
| BR0315598A (pt) | Anticorpos neutralizantes contra gdf-8 e usos dos mesmos | |
| BR9900775A (pt) | Tratamento de desordens do esqueleto. | |
| IT1285002B1 (it) | Composizione antiparassitaria per il trattamento e la protezione di animali da compagnia | |
| EP1021177A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | |
| CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
| HUP0201106A3 (en) | Method of enhancing biological effectiveness of plant treatment compositions | |
| BR9707489A (pt) | Composto composição farmacêutica e processo para tratar um paciente sofrendo de um distúrbio fisilógico | |
| HUP0004271A2 (hu) | Elhízás kezelésére szolgáló, amilint vagy amilin-agonistát tartalmazó készítmények | |
| DK0951909T4 (da) | Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf | |
| ID28460A (id) | Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol | |
| DK0988040T3 (da) | Anvendelse af glucosamin og glucasamin-derivater til hurtig lindring af klöe eller lokaliseret smerte | |
| RU2001114216A (ru) | Средство для лечения патологического костного метаболизма | |
| BR0211936A (pt) | Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos | |
| WO1998032428A3 (en) | Compositions comprising choline and use of choline to treat endotoxic shock | |
| WO2002064160A3 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
| PT1128841E (pt) | Composicao farmaceutica contendo um antagonista de receptor para o tratamento de disturbios da coagulacao sanguinea | |
| ATE344664T1 (de) | Verbesserte methode zur eradikation von helicobacter pylori | |
| BR9503890A (pt) | Composição cosmética processo de preparação da mesma processo de prevenção ou de atenuação da foto-reatividade de nanopigmentos de dióxido de titânio e processo de tratamento cosmético da pele | |
| ITVI980244A0 (it) | Struttura di fissatore esterno per il trattamento di fratture, dislocazioni e rigidita' post-traumatiche dell'articolazione del | |
| DK0865286T3 (da) | Præparater omfattende bismuth og et eller flere antimikrobielle midler til forebyggelse og behandling af gastrointestinale lidelser | |
| RU2045937C1 (ru) | Устройство для остеосинтеза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20071029 |